These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 26553)
1. The physiological disposition of (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid in the rat, dog, rhesus monkey, and baboon. Zacchei AG; Wishousky TI; Watson LS Drug Metab Dispos; 1978; 6(3):313-20. PubMed ID: 26553 [No Abstract] [Full Text] [Related]
2. The metabolism of (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid in chimpanzee and man. Zacchei AG; Wishousky TI; Arison BH; Hitzenberger G Drug Metab Dispos; 1978; 6(3):303-12. PubMed ID: 26552 [TBL] [Abstract][Full Text] [Related]
3. The physiological disposition of the uricosuric-saluretic agent (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy)acetic acid (MK-196) in the rat, dog, and monkey. Zacchei AG; Wishousky TI Drug Metab Dispos; 1976; 4(5):490-8. PubMed ID: 10149 [TBL] [Abstract][Full Text] [Related]
4. GLC determination of the polyvalent saluretic uricosuric agent (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid in biological fluids. Zacchei AG; Wishousky TI J Pharm Sci; 1978 Feb; 67(2):162-4. PubMed ID: 413902 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Timchalk C; Nolan RJ Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410 [TBL] [Abstract][Full Text] [Related]
6. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Hucker HB; Stauffer SC; White SD; Rhodes RE; Arison BH; Umbenhauer ER; Bower RJ; McMahon FG Drug Metab Dispos; 1973; 1(6):721-36. PubMed ID: 4156293 [No Abstract] [Full Text] [Related]
7. Pharmacokinetics and metabolism of cefazedone in Wistar rat, beagle dog and rhesus monkey. Sailer H; Diekmann HW; Faro HP; Garbe A Arzneimittelforschung; 1979; 29(2a):404-11. PubMed ID: 114189 [No Abstract] [Full Text] [Related]
8. Metabolism and disposition of sulfinalol in laboratory animals. Benziger DP; Fritz A; Edelson J Drug Metab Dispos; 1981; 9(6):493-8. PubMed ID: 6120804 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. Krause W; Kühne G Drug Metab Dispos; 1983; 11(2):91-6. PubMed ID: 6133729 [TBL] [Abstract][Full Text] [Related]
10. Physiological disposition and plasma metabolites of a new anti-inflammatory agent, diftalone, in rat, dog, monkey and man. Benedetti MS; Assandri A; Schelling JL; Villani F Arzneimittelforschung; 1977; 27(12):2364-8. PubMed ID: 414763 [No Abstract] [Full Text] [Related]
11. Species differences in the disposition and metabolism of 6,11-dihydro-11-oxodibenz[be]oxepin-2-acetic acid (isoxepac) in rat, rabbit, dog, rhesus monkey, and man. Illing HP; Fromson JM Drug Metab Dispos; 1978; 6(5):510-7. PubMed ID: 30600 [TBL] [Abstract][Full Text] [Related]
12. Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Hucker HB; Stauffer SC; Balletto AJ; White SD; Zacchei AG; Arison BH Drug Metab Dispos; 1978; 6(6):659-72. PubMed ID: 33029 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. Salmon J; Coussediere D; Cousty C; Raynaud JP J Steroid Biochem; 1983 Aug; 19(2):1223-34. PubMed ID: 6887930 [TBL] [Abstract][Full Text] [Related]
14. Disposition and metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine in rats, dogs, and monkeys. Hucker HB; Hutt JE; White SD; Arison BH; Zacchei AG Drug Metab Dispos; 1983; 11(1):54-8. PubMed ID: 6132797 [TBL] [Abstract][Full Text] [Related]
15. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses. Yakatan GJ; Maness DD; Scholler J; Johnston JT; Novick WJ; Doluisio JT Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):465-82. PubMed ID: 109903 [TBL] [Abstract][Full Text] [Related]
16. GLC determination of a novel polyvalent saluretic agent, (6,7-dichloro-2-methyl-1-oxo-2-phenyl-5-indanyloxy)acetic acid, in biological fluids. Zacchei AG; Wishousky T J Pharm Sci; 1976 Dec; 65(12):1770-3. PubMed ID: 829793 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the anxiolytic beta-carboline derivative abecarnil in the mouse, rat, rabbit, dog, cynomolgus monkey and baboon. Studies on species differences. Krause W; Mengel H Arzneimittelforschung; 1990 May; 40(5):522-9. PubMed ID: 1974427 [TBL] [Abstract][Full Text] [Related]
18. The disposition and metabolism of 5-(4,5-dihydro-2-phenylbenz[e]indol-3-yl)salicylic acid (fendosal) in the rat, mouse, rabbit, do, rhesus monkey, and man. Warrander A; Metcalf R; Fromson JM Drug Metab Dispos; 1981; 9(2):161-7. PubMed ID: 6113117 [TBL] [Abstract][Full Text] [Related]
19. (1-oxo-2-substituted-5-indanyloxy)acetic acids, a new class of potent renal agents possessing both uricosuric and saluretic activity. A reexamination of the role of sulfhydryl binding in the mode of action of acylphenoxyacetic acidsaluretics. Cragoe EJ; Schultz EM; Schneeberg JD; Stokker GE; Woltersdorf OW; Fanelli GM; Watson LS J Med Chem; 1975 Feb; 18(2):225-8. PubMed ID: 1120997 [No Abstract] [Full Text] [Related]
20. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. Evans GH; Nies AS; Shand DG J Pharmacol Exp Ther; 1973 Jul; 186(1):114-22. PubMed ID: 4198771 [No Abstract] [Full Text] [Related] [Next] [New Search]